Soliton Inc. (NASDAQ: SOLY) Signs Partnership with Global Medical Device Manufacturer Sanmina Corp.

• Company has signed partnership with Sanmina Corp., a global contract electronics manufacturer, that sets the foundation for the commercialization and launch of products
• SOLY’s Rapid Acoustic Pulse device, designed to use shockwaves to accelerate tattoo removal, received institutional review board approval as a non-significant risk device
• Higher energy versions of acoustic pulse devices are in early stages of development for potential treatment of cellulite and other indications

Soliton Inc. (NASDAQ: SOLY) has reached an agreement with Sanmina, one of the world’s largest medical device manufacturers, to provide the design and testing to advance Soliton’s Rapid Acoustic Pulse (“RAP”) device for use in future clinical trials. The successful execution of this strategy is expected to lay the foundation for a commercial launch of Soliton’s products (http://ibn.fm/NLeYu).

RAP is a device that uses proprietary platform technology licensed from the MD Anderson Cancer Center. The device is designed to use rapid pulses of acoustic shockwaves together with existing lasers to accelerate the removal of unwanted tattoos.

Soliton also announced that its RAP device received institutional review board approval as a non-significant risk device. The FDA-registered board has been designated to review and monitor biomedical research involving human subjects. Subsequently, Soliton conducted several human clinical trials to study the use of the RAP device to accelerate tattoo fading and also initiated a proof-of-concept trial in humans for the reduction of cellulite (http://ibn.fm/iAY14).

“Working with Sanmina in this commercialization phase not only provides us with world-class quality and documentation, but we also believe it will make for a smoother transition to manufacturing, which we expect to begin here in the US later this year,” Soliton CEO Dr. Chris Capelli stated in a news release.

Based in Houston, Texas, Soliton is a medical device company with a proprietary platform technology licensed from the University of Texas on behalf of MD Anderson.

Also in the early stages of development is a device that uses higher energy versions of acoustic pulse devices for potential stand-alone treatment of cellulite and other indications. Both products by Soliton are investigational and not yet available for sale in the United States.

For more information, visit the company’s website at www.Soliton.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php